bi 1482694
Small moleculeexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2012 (NCT01588145)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545430 ↗
- ChEMBLCHEMBL3544969 ↗
Also known as
- bi 1482694
- bi 1482694
- hm61713
- hm61713
- hm-61713
- hm-61713
- hm71224
- hm71224
- hm-71224
- hm-71224
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02722161 | Phase 1 | Apr 1, 2016 | Boehringer Ingelheim |
| NCT02485652 | Phase 2 | Jul 1, 2015 | Hanmi Pharmaceutical, Harvard University, Sungkyunkwan University |
| NCT02444819 | Phase 2 | Mar 1, 2015 | Hanmi Pharmaceutical, Sungkyunkwan University |
| NCT01894399 | Phase 1 | Sep 1, 2013 | Hanmi Pharmaceutical, Seoul National University |
| NCT01765478 | Phase 1 | Jan 1, 2013 | Hanmi Pharmaceutical, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT01588145 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2012 | Hanmi Pharmaceutical, Seoul National University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanmi Pharmaceutical | For profit | 5 | 5 | 2 | 2012 |
| Seoul National University | Academic/Hospital | 2 | 0 | 2 | 2012 |
| Sungkyunkwan University | Academic/Hospital | 2 | 0 | 1 | 2015 |
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 2016 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2013 |
6 organizations
Page 1 / 1